Aberrant JAK3 activation and its downstream signaling pathways are implicated in the pathogenesis of CTCL, and inhibition of JAK3 has been a therapeutic strategy for CTCL with increasing attentions. The gene discussed is JAK3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.